Melanotan II

Melanotan II is a synthetic analogue of the peptide hormone melanocyte-stimulating hormone (MSH) that stimulates melanogenesis and increases sexual arousal. It was originally developed by researchers at the University of Arizona to provide a potential way to prevent skin cancer through artificial tanning.

History

Melanotan II was first synthesized at the University of Arizona. Researchers there knew that one of the best defenses against skin cancer was a natural tan which develops as a protective response to UV exposure. Their goal was to find a way to effectively reduce the risk of skin cancer in individuals, particularly those with fair skin who are most at risk.

Mechanism of Action

Melanotan II works by stimulating the release of alpha-melanocyte-stimulating hormone (α-MSH). This peptide hormone, produced in the pituitary gland, initiates a cascade of events that leads to melanogenesis, a process by which the skin's pigment cells (melanocytes) produce the pigment melanin.

Uses

Melanotan II has been reported to increase the darkening of the skin (a process known as tanning) without the need for exposure to harmful ultraviolet radiation. This makes it a potential candidate for the prevention of skin cancer, as it could potentially be used to create a tan without the need for sun exposure.

In addition to its tanning effects, Melanotan II has also been found to act as a potent aphrodisiac. It has been shown to increase sexual desire and function in both men and women, and has been used in the treatment of erectile dysfunction.

Side Effects

Like all medicines, Melanotan II can cause side effects, although not everybody gets them. The most common side effects include nausea, stomach cramps, decreased appetite, flushing, tiredness, yawning, darkened skin, spontaneous erections of the penis, and others.

Legal Status

Melanotan II is not approved for use by any governmental health authority, including the Food and Drug Administration (FDA) in the United States, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, or the Therapeutic Goods Administration (TGA) in Australia.

See Also

• Melanocyte-stimulating hormone
• Melanogenesis
• Erectile dysfunction